Treat to target strategy in early rheumatoid arthritis versus routine care – A comparative clinical practice study-Reference-Cited by-同舟云学术

Treat to target strategy in early rheumatoid arthritis versus routine care – A comparative clinical practice study

Published:2019-04 Issue:5 Volume:48 Page:808-814
ISSN:0049-0172
Container-title:Seminars in Arthritis and Rheumatism
language:en
Short-container-title:Seminars in Arthritis and Rheumatism

Author:

Brinkmann Gina Hetland,Norvang Vibeke,Norli Ellen Sauar,Grøvle Lars,Haugen Anne Julsrud^ORCID,Lexberg Åse Stavland^ORCID,Rødevand Erik,Bakland Gunnstein,Nygaard Halvor,Krøll Frode,Widding-Hansen Inger Johanne,Bjørneboe Olav,Thunem Cathrine,Kvien Tore,Mjaavatten Maria Dahl,Lie Elisabeth

Publisher

Elsevier BV

Subject

Anesthesiology and Pain Medicine,Rheumatology

Reference38 articles.

1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update;Smolen;Ann Rheum Dis,2017

2. The new ACR/EULAR remission criteria: rationale for developing new criteria for remission;Bykerk;Rheumatology (Oxford),2012

3. Systematic monitoring of disease activity using an outcome measure improves outcomes in rheumatoid arthritis;Katchamart;J Rheumatol,2010

4. Treating rheumatoid arthritis to target: recommendations of an international task force;Smolen;Ann Rheum Dis,2010

5. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force;Smolen;Ann Rheum Dis,2016

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of treat-to-target strategy studies in rheumatic diseases: A systematic review and meta-analysis;Seminars in Arthritis and Rheumatism;2024-08

2. Differences in referral path, clinical and radiographic outcomes between seronegative and seropositive rheumatoid arthritis Mexican Mestizo patients: A cohort study;PLOS ONE;2024-06-06

3. Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study;RMD Open;2024-06

4. Effectiveness of a treat-to-target strategy in patients with moderate to severely active rheumatoid arthritis treated with abatacept;Arthritis Research & Therapy;2023-09-28

5. Rheumatoid arthritis as a clinical and immunological syndrome: focus on the seronegative subtype of the disease;Rheumatology Science and Practice;2023-06-28